全文获取类型
收费全文 | 4095篇 |
免费 | 218篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 53篇 |
妇产科学 | 51篇 |
基础医学 | 534篇 |
口腔科学 | 118篇 |
临床医学 | 301篇 |
内科学 | 1292篇 |
皮肤病学 | 88篇 |
神经病学 | 351篇 |
特种医学 | 97篇 |
外科学 | 597篇 |
综合类 | 21篇 |
一般理论 | 1篇 |
预防医学 | 191篇 |
眼科学 | 68篇 |
药学 | 243篇 |
中国医学 | 8篇 |
肿瘤学 | 291篇 |
出版年
2023年 | 28篇 |
2022年 | 56篇 |
2021年 | 95篇 |
2020年 | 61篇 |
2019年 | 73篇 |
2018年 | 108篇 |
2017年 | 68篇 |
2016年 | 81篇 |
2015年 | 104篇 |
2014年 | 157篇 |
2013年 | 184篇 |
2012年 | 274篇 |
2011年 | 282篇 |
2010年 | 166篇 |
2009年 | 151篇 |
2008年 | 281篇 |
2007年 | 296篇 |
2006年 | 263篇 |
2005年 | 299篇 |
2004年 | 276篇 |
2003年 | 251篇 |
2002年 | 208篇 |
2001年 | 26篇 |
2000年 | 23篇 |
1999年 | 29篇 |
1998年 | 35篇 |
1997年 | 30篇 |
1996年 | 33篇 |
1995年 | 42篇 |
1994年 | 30篇 |
1993年 | 25篇 |
1992年 | 28篇 |
1991年 | 20篇 |
1990年 | 18篇 |
1989年 | 10篇 |
1988年 | 12篇 |
1987年 | 18篇 |
1986年 | 10篇 |
1985年 | 7篇 |
1984年 | 20篇 |
1983年 | 18篇 |
1982年 | 18篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 6篇 |
1977年 | 9篇 |
1976年 | 6篇 |
1975年 | 10篇 |
1957年 | 5篇 |
1944年 | 5篇 |
排序方式: 共有4348条查询结果,搜索用时 437 毫秒
91.
McMurray J Cohen-Solal A Dietz R Eichhorn E Erhardt L Hobbs FD Krum H Maggioni A McKelvie RS Piña IL Soler-Soler J Swedberg K 《European journal of heart failure》2005,7(5):710-721
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of pharmacological agents into clinical practice, thereby denying patients with heart failure (HF) the benefits of drug treatments proven to improve well-being and prolong life. This may be due to unfamiliarity with the evidence-base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events. ACE inhibitors have long been the cornerstone of therapy for systolic HF irrespective of aetiology. Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome. In order to accelerate the safe uptake of these treatments and to ensure that all eligible patients receive the most appropriate medications, a clear and concise set of clinical recommendations has been prepared by a group of clinicians with practical expertise in the management of HF. The objective of these recommendations is to provide practical guidance for non-specialists, in order to increase the use of evidenced based therapy for HF. These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines. 相似文献
92.
Fabio De Conti Francesco Corbetti Giorgio De Conti Enzo Mantovani Attilio Di Marco Aldo Zampiero Piergiuseppe Piovesana 《Italian heart journal》2005,6(2):160-163
Calcification of the mitral annulus is a common echocardiographic finding in the elderly, particularly in females. Calcium deposits are generally located in the posterior mitral ring, sometimes extending to the whole mitral annulus and involving the mitral valve apparatus. The present report refers to 2 patients with a very atypical mass-like calcification of the mitral annulus resembling a cardiac tumor. A detailed evaluation of the mass was obtained at transthoracic and transesophageal echocardiography; the differential diagnosis with other intracardiac masses was aided by the use of computed tomography and magnetic resonance imaging. To our knowledge there has been no prior report of such a lesion evaluated at cardiac magnetic resonance imaging. 相似文献
93.
Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma 总被引:1,自引:0,他引:1
Aldo Montuoro Luca De Rosa Angelo De Blasio Leonardo Pacilli Nicola Petti Antonio De Laurenzi 《British journal of haematology》1990,76(3):365-368
Alpha-2a-interferon (IFN) has demonstrable activity in advance and refractory multiple myeloma (MM), because of the in vitro synergism between IFNs and cytotoxic agents we report the preliminary results of a therapeutic trial of 50 patients with MM. Twenty-eight patients were randomized to receive melphalan plus prednisone (MP) and 22 were randomized to receive IFN plus MP (IFN-MP). Criteria for response, progression and relapse were those of the Southwestern Oncology Group. 95% of the patients receiving IFN-MP responded to therapy as opposed to 68% of the patients receiving MP (P less than 0.05). Response was independent of M-component immunoglobulin class but in stage III it was higher in the IFN-MP group than in the MP group (P less than 0.05). The combination IFN-MP was well tolerated without unusual or unexpected toxic effects. The response duration time was longer in the IFN-MP group than in the MP group (P less than 0.025). The median survival was 80 weeks in the MP group and in the IFN-MP group the 93% of patients were still alive after 90 weeks (P less than 0.025). Our results show that the use of the IFN as an adjuvant to MP improves the percentage of responders, the response duration time and the median survival of untreated patients with MM. 相似文献
94.
Leleu X Eeckhoute J Jia X Roccaro AM Moreau AS Farag M Sacco A Ngo HT Runnels J Melhem MR Burwick N Azab A Azab F Hunter Z Hatjiharissi E Carrasco DR Treon SP Witzig TE Hideshima T Brown M Anderson KC Ghobrial IM 《Blood》2008,111(10):5068-5077
The nuclear factor-B (NF-B) path-way has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-B pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-B activity. We demonstrated that perifosine and bortezomib both targeted NF-B through its recruitment to the promoter of its target gene IB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-B pathway. 相似文献
95.
96.
A Randomized, Controlled Study of Thymosin-α1 Therapy in Patients with Anti-HBe, HBV-DNA-Positive Chronic Hepatitis B 总被引:5,自引:0,他引:5
Zavaglia C Severini R Tinelli C Franzone JS Airoldi A Tempini S Bettale G Ideo G 《Digestive diseases and sciences》2000,45(4):690-696
No consistently effective therapy is yet available for the treatment of chronic HBsAg, anti-HBe, HBV-DNA-positive hepatitis. A multicenter trial has shown that the response rates are not significantly different when patients with anti-HBe-positive hepatitis are treated with six-month course of thymosin-1 or of interferon-. However, since among these patients, interferon's real efficacy is still debated, with sustained biochemical response achieved in only a few of the treated patients, we conducted this controlled study to investigate the safety and efficacy of thymosin-1 as compared with no treatment. Forty-four chronic hepatitis B virus (HBV) carriers, who were anti-HBe- and HBV-DNA-positive, were randomized, with stratification for the presence of cirrhosis at baseline liver biopsy, to receive either thymosin-1 at a dose of 900 g/m2 twice a week for six months or no treatment. At entry, both groups of patients were comparable for sex, age, liver histology, ALT, IgM anti-HBc, and HBV-DNA levels. Forty-two patients were followed-up for 20 months (median; range 12–32 months) after completion of therapy: one dropped out, and one developed hepatocellular carcinoma at six months. Thymosin-1 treatment had no side effects. Six months after the end of the therapy, HBV-DNA was negative and ALT had normalized in 14% of treated cases and in 4.5% of control group, while IgM anti-HBc was negative (<0.200) in 14% of the treated patients and in 4.5% of the controls. Among the treated patients, the median ALT levels stayed significantly lower compared to the pretreatment values during the treatment period and six months of follow-up. During the first year, there were six flares of hepatitis in the control group and five among the treated patients (P = NS), yielding a per year average of 0.3 and 0.23 flares per patient, respectively. Among the treated patients, median IgM anti-HBc levels were low with respect to baseline values 4–10 months after treatment started. None became HBsAg negative. In conclusion, these results indicate that, in anti-HBe, HBV-DNA-positive chronic hepatitis B, thymosin-1 therapy alone does not increase the response rate, but may contribute to reduce the immune-mediated liver cell necrosis as indirectly assessed by ALT and IgM anti-HBc levels. 相似文献
97.
98.
99.
Luca Passamonti Francesco Fera Alessandro Tessitore Antonio Russo Antonio Cerasa Cecilia M. Gioia Maria R. Monsurrò Raffaella Migliaccio Gioacchino Tedeschi Aldo Quattrone 《Neurobiology of aging》2013
Previous studies have shown that affective symptoms are part of the clinical picture in amyotrophic lateral sclerosis (ALS), the most common motor neuron disorder in elderly people. Diffuse neurodegeneration of limbic regions (e.g., prefrontal cortex [PFC], amygdala) was demonstrated in ALS post-mortem, although the mechanisms of emotional dysregulation in ALS in vivo remain unclear. Using functional imaging, we assessed the brain responses to emotional faces in 11 cognitively unimpaired ALS patients and 12 healthy controls (HCs). We tested whether regional activities and connectivity patterns in the limbic system differed between ALS patients and HCs and whether the variability in clinical measures modulated the neuroimaging data. Relative to HCs, ALS patients displayed greater activation in a series of PFC areas and altered left amygdala–PFC connectivity. Anxiety modulated the right amygdala–PFC connectivity in HCs but not in ALS patients. Reduced right premotor cortex activity and altered left amygdala–supplementary motor area connectivity were associated with longer disease duration and greater disease severity, respectively. Our findings demonstrate dysfunctions of the limbic system in ALS patients at early stages of the disease, and extend our knowledge about the interplay between emotional brain areas and the regions traditionally implicated in motor control. 相似文献
100.
Antonella Orlando Caterina Messa Michele Linsalata Aldo Cavallini 《Immunopharmacology and immunotoxicology》2013,35(1):108-116
Previous in vitro and in vivo studies have suggested that lactobacilli can exert antiproliferative effects on the gastrointestinal epithelium. However, their role in affecting the cellular proliferative mechanisms is not completely clear. The aim of this study was to investigate the effects of increasing concentrations of Lactobacillus rhamnosus strain GG (L. GG) homogenate on cell growth and proliferation (by MTT, [3H]-thymidine incorporation and polyamine biosynthesis) in neoplasms originating from different gastrointestinal tracts. Thus, HGC-27 human gastric cancer cells and DLD-1 human colonic adenocarcinoma cells were evaluated. Besides, in order to verify which bacterial fraction was involved in the antiproliferative effects, the cytoplasm and cell wall extracts were tested separately. Gastric HGC-27 and colonic DLD-1 cells showed significant differences in their proliferative behavior, in particular in their polyamine profile and biosynthesis. Notwithstanding, one and the other proved to be sensitive to the growth inhibition by the highest concentrations of bacterial homogenate. Both HGC-27 and DLD-1 cells were resistant to the bacterial cell wall fractions, whereas increasing cytoplasm fraction concentrations induced an evident antiproliferative effect. These data suggest that cytoplasm extracts could be the responsible for L. GG action on proliferation in these two cell lines from gastric and colonic neoplasms. 相似文献